These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 30944812)

  • 1. A Meta-analysis of the Value of vWF in the Diagnosis of Liver Cirrhosis with Portal Hypertension.
    Ding XC; Ma WL; Li MK; Liu SW; Liu XY; Hai L; Luo X; Hu YC; Ma LN
    J Clin Transl Hepatol; 2019 Mar; 7(1):3-8. PubMed ID: 30944812
    [No Abstract]   [Full Text] [Related]  

  • 2. von Willebrand factor as a biomarker of clinically significant portal hypertension and severe portal hypertension: a systematic review and meta-analysis.
    Zou Z; Yan X; Li C; Li X; Ma X; Zhang C; Ju S; Tian J; Qi X
    BMJ Open; 2019 Aug; 9(8):e025656. PubMed ID: 31473610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis.
    Ferlitsch M; Reiberger T; Hoke M; Salzl P; Schwengerer B; Ulbrich G; Payer BA; Trauner M; Peck-Radosavljevic M; Ferlitsch A
    Hepatology; 2012 Oct; 56(4):1439-47. PubMed ID: 22532296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. von Willebrand factor as a novel noninvasive predictor of portal hypertension and esophageal varices in hepatitis B patients with cirrhosis.
    Wu H; Yan S; Wang G; Cui S; Zhang C; Zhu Q
    Scand J Gastroenterol; 2015; 50(9):1160-9. PubMed ID: 25877661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension.
    La Mura V; Reverter JC; Flores-Arroyo A; Raffa S; Reverter E; Seijo S; Abraldes JG; Bosch J; García-Pagán JC
    Gut; 2011 Aug; 60(8):1133-8. PubMed ID: 21427197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Shear-wave elastography: a noninvasive tool for monitoring changing hepatic venous pressure gradients in patients with cirrhosis.
    Choi SY; Jeong WK; Kim Y; Kim J; Kim TY; Sohn JH
    Radiology; 2014 Dec; 273(3):917-26. PubMed ID: 25025464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severity.
    Mandorfer M; Schwabl P; Paternostro R; Pomej K; Bauer D; Thaler J; Ay C; Quehenberger P; Fritzer-Szekeres M; Peck-Radosavljevic M; Trauner M; Reiberger T; Ferlitsch A;
    Aliment Pharmacol Ther; 2018 Apr; 47(7):980-988. PubMed ID: 29377193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced processing of von Willebrand factor reflects disease severity and discriminates severe portal hypertension in cirrhosis.
    Langholm LL; Manon-Jensen T; Karsdal MA; Bendtsen F; Leeming DJ; Møller S
    Eur J Gastroenterol Hepatol; 2019 Aug; 31(8):1040-1048. PubMed ID: 30768435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-invasive aspartate aminotransferase to platelet ratio index correlates well with invasive hepatic venous pressure gradient in cirrhosis.
    Kirnake V; Arora A; Sharma P; Goyal M; Chawlani R; Toshniwal J; Kumar A
    Indian J Gastroenterol; 2018 Jul; 37(4):335-341. PubMed ID: 30178093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Von Willebrand factor antigen for detection of hepatopulmonary syndrome in patients with cirrhosis.
    Horvatits T; Drolz A; Roedl K; Herkner H; Ferlitsch A; Perkmann T; Müller C; Trauner M; Schenk P; Fuhrmann V
    J Hepatol; 2014 Sep; 61(3):544-9. PubMed ID: 24798623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transient elastography versus hepatic venous pressure gradient for diagnosing portal hypertension: a systematic review and meta-analysis.
    Kim G; Kim MY; Baik SK
    Clin Mol Hepatol; 2017 Mar; 23(1):34-41. PubMed ID: 28263953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Damping index of Doppler hepatic vein waveform to assess the severity of portal hypertension and response to propranolol in liver cirrhosis: a prospective nonrandomized study.
    Kim MY; Baik SK; Park DH; Lim DW; Kim JW; Kim HS; Kwon SO; Kim YJ; Chang SJ; Lee SS
    Liver Int; 2007 Oct; 27(8):1103-10. PubMed ID: 17845539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical value of contrast-enhanced ultrasound in evaluating portal hypertension in patients with decompensated liver cirrhosis].
    Zhuang Y; Ding H; Han H; Mao F; Luo JJ; Chen SY; Wang WP
    Zhonghua Gan Zang Bing Za Zhi; 2016 Apr; 24(4):270-4. PubMed ID: 27470625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Portal hypertension in patients with cirrhosis: indirect assessment of hepatic venous pressure gradient by measuring azygos flow with 2D-cine phase-contrast magnetic resonance imaging.
    Gouya H; Grabar S; Vignaux O; Saade A; Pol S; Legmann P; Sogni P
    Eur Radiol; 2016 Jul; 26(7):1981-90. PubMed ID: 26373753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma Nogo-A and placental growth factor levels are associated with portal hypertension in patients with liver cirrhosis.
    Gelman S; Salteniene V; Pranculis A; Skieceviciene J; Zykus R; Petrauskas D; Kupcinskas L; Canbay A; Link A; Kupcinskas J
    World J Gastroenterol; 2019 Jun; 25(23):2935-2946. PubMed ID: 31249451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of transient elastography with hepatic venous pressure gradient in patients with cirrhotic portal hypertension: A study of 326 patients from India.
    Kumar A; Khan NM; Anikhindi SA; Sharma P; Bansal N; Singla V; Arora A
    World J Gastroenterol; 2017 Jan; 23(4):687-696. PubMed ID: 28216976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Portal Hypertension in Patients with Liver Cirrhosis: Diagnostic Accuracy of Spleen Stiffness.
    Takuma Y; Nouso K; Morimoto Y; Tomokuni J; Sahara A; Takabatake H; Matsueda K; Yamamoto H
    Radiology; 2016 May; 279(2):609-19. PubMed ID: 26588019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of von Willebrand Factor Antigen in Predicting Survival of Patients with HBV-Related Cirrhosis.
    Pan Y; Guo R; Lv Y; Cui D; Xie J
    Can J Gastroenterol Hepatol; 2022; 2022():9035971. PubMed ID: 35360443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indocyanine green retention test (ICG-r15) as a noninvasive predictor of portal hypertension in patients with different severity of cirrhosis.
    Pind ML; Bendtsen F; Kallemose T; Møller S
    Eur J Gastroenterol Hepatol; 2016 Aug; 28(8):948-54. PubMed ID: 27172450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The VITRO Score (Von Willebrand Factor Antigen/Thrombocyte Ratio) as a New Marker for Clinically Significant Portal Hypertension in Comparison to Other Non-Invasive Parameters of Fibrosis Including ELF Test.
    Hametner S; Ferlitsch A; Ferlitsch M; Etschmaier A; Schöfl R; Ziachehabi A; Maieron A
    PLoS One; 2016; 11(2):e0149230. PubMed ID: 26895398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.